Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab + BSC vs BSC Alone in Advanced Colorectal Adenocarcinoma
NCT02870920Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in colorectal cancer (CRC), sponsored by Canadian Cancer Trials Group. Started Oct 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02870920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870920.